Abstract: Provided is method for training communication decision model, including: training initial model according to first decision samples to adjust model parameters of initial model to obtain first trained model, first decision samples being samples of decisions already made by first communication site; acquiring at least one modification value of second model parameter of at least one second trained model, each second trained model being obtained by training initial model according to second decision samples of one second communication site, second decision samples being samples of decisions already made by the second communication site, and each modification value of second model parameter representing at least part of modifications to model parameters of second trained model relative to those of initial model; adjusting model parameters of trained model according to at least part of modification values of second model parameters to obtain communication decision model for first communication site.

Abstract: A memory system for maintaining data consistency and an operation method thereof are provided. The operation method includes: receiving a first data in a first cache of a first memory from a processor; reading the first data from the first cache and writing the first data as a redo log into a log buffer of the first memory; writing the redo log from the log buffer into a memory controller of the processor; performing an in-memory copy in a second memory to copy a second data as an undo log, wherein the second data is an old version of the first data; and writing the redo log from the memory controller into the second memory for covering the second data by the redo log as a third data, wherein the redo log, the third data and the first data are the same.

Abstract: A red blood cell (RBC) having an agent linked thereto, wherein the agent is linked to at least one endogenous, non-engineered membrane protein of the RBC by a sortase-mediated reaction, preferably by a sortase-mediated glycine conjugation and/or a sortase-mediated lysine side chain ?-amino group conjugation, which may occurring at least on glycine (n) and/or lysine ?-amino group at internal sites of the extracellular domain of at least one endogenous, non-engineered membrane protein, preferably n being 1 or 2, as well as the use of the RBC for delivering drugs and probes.

Abstract: A memory system for maintaining data consistency and an operation method thereof are provided. The operation method includes: receiving a first data in a first cache of a first memory from a processor; reading the first data from the first cache and writing the first data as a redo log into a log buffer of the first memory; writing the redo log from the log buffer into a memory controller of the processor; performing an in-memory copy in a second memory to copy a second data as an undo log, wherein the second data is an old version of the first data; and writing the redo log from the memory controller into the second memory for covering the second data by the redo log as a third data, wherein the redo log, the third data and the first data are the same.

Abstract: A high performance liquid chromatography method for analysis of a MN diagnostic and therapeutic ligand and precursors is revealed. Polarity of eluents used during elution is changed to remove impurities. First use a first eluent with a lower ratio of acetonitrile as a mobile phase to elute analytes. Then a second eluent in which a ratio of acetonitrile is increased into 97˜99% is used to elute the analytes for at least 20 minutes. Next use the first eluent to elute the analytes for at least 60 minutes. Thus no residual impurities are left in the column and the analytes remain in the column stably. Therefore a more accurate and reproductive result is obtained.

Abstract: A tetradentate organic ligand H3-MN-16Bn containing a long alkyl group, a precursor thereof, and a method for preparing the same are revealed. A precursor of H3-MN-16Bn, benzyl 16-bromohexadecanate, is obtained by esterification reaction of 16-bromohexadecanoic acid. Then bimolecular nucleophilic substitution reaction (SN2) of Benzyl 16-bromohexadecanate with nitrogen sulfide (N2S2) is carried out to get H3-MN-16Bn that is used as a standard hydrolysis metabolites of non-radioactive 185Re-complex compound.

Abstract: A tetradentate organic ligand H3-MN-16Bn containing a long alkyl group, a precursor thereof, and a method for preparing the same are revealed. A precursor of H3-MN-16Bn, benzyl 16-bromohexadecanate, is obtained by esterification reaction of 16-bromohexadecanoic acid. Then bimolecular nucleophilic substitution reaction (SN2) of Benzyl 16-bromohexadecanate with nitrogen sulfide (N2S2) is carried out to get H3-MN-16Bn that is used as a standard hydrolysis metabolites of non-radioactive 185Re-complex compound.

Abstract: The subject invention is directed to novel polynucleotides and polypeptides comprising SEQ ID NOs: 1 and 2. Also provided arc fragments these polypeptides. The polynucleotides and polypeptides disclosed herein have been isolated from the liver cells (hepatocytes) of end stage liver failure patients and appear to be associated with a poor prognosis for these patients as relates to liver function. The subject application provides therapeutic methods and reagents for treating livers in which the polynucleotide and polypeptide of SEQ ID NO: 1 and 2 are identified as well as diagnostic methods and reagents for identifying individuals at risk of liver failure. Finally, the subject invention also provides a system of the classification, revision or reordering of a classification system of liver transplant patients.

Abstract: The invention relates to a new process for preparing benzimidazole derivatives having a chiral sulfoxide group in enantiomerically pure form or in a form in which one of the two enantiomers is present in an increased quantity over the other enantiomer. The invention likewise relates to a process for preparing the salts of the individual enantiomers of the benzimidazole derivatives with a chiral sulfoxide group. The invention relates in particular to a process for preparing the S-enantiomer of omeprazole (also known as esomeprazole) and the salts thereof, more particularly the zinc salt of the S-enantiomer of omeprazole. In the new process a prochiral sulfide is oxidized in an organic solvent with an oxidizing agent in the presence of a titanium(IV) complex.